Navigation Links
Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
Date:5/12/2009

CALGARY, May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) is pleased to announce today that it has successfully completed patient enrolment in its multi-centre Phase 2 clinical trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung. A total of 52 patients have been enrolled in the trial.

"We are extremely pleased to have had the opportunity to participate in this study," said Dr. Monica Mita, principal investigator at the Institute of Drug Development (IDD), the Cancer Therapy & Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

"REOLYSIN is very well tolerated and a number of patients have derived clinical benefit. Based on the study results, which will be updated and presented at ASCO this year, further studies are planned in patients with sarcoma."

The primary statistical endpoint of the trial was met in late 2008. To meet the endpoint, at least three out of 52 patients had to experience stabilization of disease or better for more than six months. Of the 33 patients evaluable at that time, five had experienced stable disease for periods greater than six months, including one patient who had maintained stable disease for more than 16 months. An additional 10 patients had experienced stable disease for periods ranging from three to six cycles (cycle = 28 days). Updated results are scheduled to be presented May 30, 2009 at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

Clinical Trial Design

The trial (REO 014) is a Phase 2, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) led ... China , as well as solid contributions from Korea, ... / Middle East / Africa ... Germany , Turkey and the ... of sales) grew 11%, excluding U.S. HPV sales, on demand across all customer ...
(Date:7/29/2015)... ... 29, 2015 , ... G-CON Manufacturing, Inc., the leading prefabricated ... generation cell therapy POD® design. The 2nd generation portfolio not only delivers design ... POD® design. , “G-CON first offered our miniPOD CT product line to ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Neuropathology services for VA and Military health systems 2
... Leonhardt,s Launchpads ( www.leonhardtslaunchpads.com ), at the ... Center ( www.uncm.edu/STIC.php ), 2330 Circadian Way, Santa ... Grand Opening on Tuesday, November 9th from 3pm ... incubator for startup businesses and high-potential entrepreneurs in ...
... Inc. Prices $50 Million Public Offering ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Davis Phinney Foundation ( http://www.davisphinneyfoundation.org ), a non-profit foundation ... help people to live well with Parkinson,s disease, today ... Exercise and Parkinson,s: Questions and Answers from the Experts ... experts in the fields of physical therapy and exercise ...
Cached Biology Technology:OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 2OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 3OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 4OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 5OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 6OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 7OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 8OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 9Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 2Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 3Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 4
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... of Soil, they're just clever Lab guys. A team from ... Science Magazine with a new way to count bugs in ... our feet. , "Computational Improvements Reveal Great Bacterial Diversity and ... and John Dunbar, of Los Alamos' Bioscience Division, describes a ...
... CropScience and DuPont have developed two new classes of ... more effective way to fight pest insects that damage ... compounds designed to activate a novel insecticide target called ... problem of insecticide resistance, the researchers say. They described ...
... at The Schepens Eye Research Institute have discovered that ... in the eye and other parts of the body ... body's immune response and protect delicate tissues that cannot ... believe that this discovery may ultimately help in the ...
Cached Biology News:Using computers and DNA to count bacteria 2Novel compounds show promise as safer, more potent insecticides 2A protein in the eye may prevent immune response and protect eyes from disease 2
... LV Series offers high performance miniature stepper ... 23, and 34 frame sizes. These space-efficient ... life science applications, including medical instrumentation, medical ... automation systems., Meets a wide range ...
... kit for a single fragment based screening project: , ... , 96 shape-diverse mixtures of 4 (5 ... files for structure refinement , Individual compounds ... are at ca. 50 mM. Supplied in 5 96-well trays. ...
... The pTriEx™ vectors combine the proven features ... mammalian systems and provides all of the ... in one vector backbone. The pTriEx vectors ... various target genes in all three expression ...
... the first instrument engineered to match the ... by thousands of research centers worldwide. It ... which are ideally suited for high-speed temperature ... extremely high surface-area-to-volume ratio. ,By combining glass ...
Biology Products: